These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36371073)

  • 1. Therapeutics for mitochondrial dysfunction-linked diseases in Down syndrome.
    Ganguly BB; Kadam NN
    Mitochondrion; 2023 Jan; 68():25-43. PubMed ID: 36371073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondria as pharmacological targets in Down syndrome.
    Valenti D; Braidy N; De Rasmo D; Signorile A; Rossi L; Atanasov AG; Volpicella M; Henrion-Caude A; Nabavi SM; Vacca RA
    Free Radic Biol Med; 2018 Jan; 114():69-83. PubMed ID: 28838841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model.
    Valenti D; de Bari L; de Rasmo D; Signorile A; Henrion-Caude A; Contestabile A; Vacca RA
    Biochim Biophys Acta; 2016 Jun; 1862(6):1093-104. PubMed ID: 26964795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triplication of HSA21 on alterations in structure and function of mitochondria.
    Ganguly BB; Kadam NN
    Mitochondrion; 2022 Jul; 65():88-101. PubMed ID: 35623559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an overview of Down syndrome, autism, Fragile X and Rett syndrome.
    Valenti D; de Bari L; De Filippis B; Henrion-Caude A; Vacca RA
    Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():202-17. PubMed ID: 24548784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: A harmful synergistic path in down syndrome.
    Lanzillotta C; Tramutola A; Di Giacomo G; Marini F; Butterfield DA; Di Domenico F; Perluigi M; Barone E
    Free Radic Biol Med; 2021 Mar; 165():152-170. PubMed ID: 33516914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial Dysfunction in Down Syndrome: From Pathology to Therapy.
    Tan KL; Lee HC; Cheah PS; Ling KH
    Neuroscience; 2023 Feb; 511():1-12. PubMed ID: 36496187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial biogenesis: pharmacological approaches.
    Valero T
    Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic and Growth Rate Alterations in Lymphoblastic Cell Lines Discriminate Between Down Syndrome and Alzheimer's Disease.
    Coskun P; Helguera P; Nemati Z; Bohannan RC; Thomas J; Samuel SE; Argueta J; Doran E; Wallace DC; Lott IT; Busciglio J
    J Alzheimers Dis; 2017; 55(2):737-748. PubMed ID: 27802222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative stress and mitochondrial dysfunction in Down syndrome.
    Pagano G; Castello G
    Adv Exp Med Biol; 2012; 724():291-9. PubMed ID: 22411251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Drp1-mediated mitochondrial fission improves mitochondrial dynamics and bioenergetics stimulating neurogenesis in hippocampal progenitor cells from a Down syndrome mouse model.
    Valenti D; Rossi L; Marzulli D; Bellomo F; De Rasmo D; Signorile A; Vacca RA
    Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3117-3127. PubMed ID: 28939434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antioxidants in Down syndrome.
    Lott IT
    Biochim Biophys Acta; 2012 May; 1822(5):657-63. PubMed ID: 22206998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Shape of Mitochondrial Dysfunction in Down Syndrome.
    Zamponi E; Helguera PR
    Dev Neurobiol; 2019 Jul; 79(7):613-621. PubMed ID: 30830726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia.
    Perluigi M; Butterfield DA
    Curr Gerontol Geriatr Res; 2012; 2012():724904. PubMed ID: 22203843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress and Down syndrome. Do antioxidants play a role in therapy?
    Muchová J; Žitňanová I; Ďuračková Z
    Physiol Res; 2014; 63(5):535-42. PubMed ID: 24908086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive downregulation of mitochondrial function in down syndrome.
    Helguera P; Seiglie J; Rodriguez J; Hanna M; Helguera G; Busciglio J
    Cell Metab; 2013 Jan; 17(1):132-40. PubMed ID: 23312288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurological phenotypes for Down syndrome across the life span.
    Lott IT
    Prog Brain Res; 2012; 197():101-21. PubMed ID: 22541290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain.
    Butterfield DA; Di Domenico F; Swomley AM; Head E; Perluigi M
    Biochem J; 2014 Oct; 463(2):177-89. PubMed ID: 25242166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives.
    Lanzillotta C; Di Domenico F; Perluigi M; Butterfield DA
    CNS Drugs; 2019 Oct; 33(10):957-969. PubMed ID: 31410665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plant polyphenols as natural drugs for the management of Down syndrome and related disorders.
    Vacca RA; Valenti D; Caccamese S; Daglia M; Braidy N; Nabavi SM
    Neurosci Biobehav Rev; 2016 Dec; 71():865-877. PubMed ID: 27826066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.